Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659592 | 0.83 | HCRTR2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL1082640 | 0.81 | HCRTR2 (0.37) | HCRTR2HCRTR1 | |
| SCHEMBL660300 | 0.76 | CDK4 (0.66) | — | |
| SCHEMBL4828611 | 0.73 | CCND1 (0.49) | — | |
| SCHEMBL31637530 | 0.73 | CCND1 (0.49) | — | |
| SCHEMBL10192642 | 0.71 | CDK4 (0.60) | — | |
| SCHEMBL29990953 | 0.71 | CCND1 (0.56) | — | |
| SCHEMBL574660 | 0.71 | CCND1 (0.56) | — | |
| SCHEMBL10192608 | 0.71 | HTR1A (0.34) | HCRTR2HCRTR1 | |
| SCHEMBL4828470 | 0.70 | CCND1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2453896-A2 | METHODS FOR TREATING SCHIZOPHRENIA | Afraxis, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | HCRTR2 1162/4885HCRTR1 1976/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | HCRTR2 1732/4885HCRTR1 1712/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | HCRTR2 153/4885HCRTR1 313/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | HCRTR2 671/4885HCRTR1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.